Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 5/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12009462 | 0.84 | P2RX7 (0.50) | IDO1TDO2P2RX7PDE2ACCR1 | |
| SCHEMBL20288912 | 0.82 | PDE2A (0.56) | IDO1TDO2P2RX7PDE2ACTSS | |
| SCHEMBL14120782 | 0.81 | IDO1 (0.51) | IDO1TDO2P2RX7PDE2ACCR1 | |
| SCHEMBL4234796 | 0.81 | IDO1 (0.51) | IDO1TDO2P2RX7PDE2ACCR1 | |
| SCHEMBL29656429 | 0.81 | IDO1 (0.51) | IDO1TDO2P2RX7PDE2ACCR1 | |
| SCHEMBL25019477 | 0.81 | IDO1 (0.47) | IDO1TDO2P2RX7PDE2ACCR1 | |
| SCHEMBL13328616 | 0.81 | IDO1 (0.47) | IDO1TDO2P2RX7PDE2ACCR1 | |
| SCHEMBL4550765 | 0.81 | IDO1 (0.51) | IDO1TDO2P2RX7PDE2ACCR1 | |
| SCHEMBL21132890 | 0.81 | IDO1 (0.47) | IDO1TDO2P2RX7PDE2ACCR1 | |
| SCHEMBL29845425 | 0.81 | IDO1 (0.51) | IDO1TDO2P2RX7PDE2ACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | IDO1 62/4885TDO2 3097/4885P2RX7 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.